CONTENTS

SPECIAL SECTION ON PREDICTION OF HUMAN PHARMACOKINETIC PARAMETERS FROM IN VITRO SYSTEMS

Prediction of Human Pharmacokinetics in 2013 and Beyond. J. Brian Houston .......................... 1973

A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthena V. Varma, and R. Scott Obach .................. 1975


CYP2B6 Pharmacogenetics—Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li, and Zeruesenay Desta .......... 2004

In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Biopharmaceutics Drug Disposition Classification System Class. Ryota Kikuchi, Sonia M. de Morais, and J. Cory Kalvass .................. 2012


Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani, and Donald Tweedie ........ 2024


SHORT COMMUNICATION


ARTICLES

N-Acetylation of Etamicastat, a Reversible Dopamine-β-Hydroxylase Inhibitor. Ana I. Loureiro, Carlos Fernandes-Lopes, Maria João Bonifácio, Lyndon C. Wright, and Patrício Soares-da-Silva .... 2081

Continued on next page
Activity, Inhibition, and Induction of Cytochrome P450 2J2 in Adult Human Primary Cardiomyocytes. Eric A. Evangelista, Rüdiger Kaspera, Nahush A. Mokadam, J. P. Jones, III, and Rheem A. Totah. 2087

Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. Hong Shen, Zheng Yang, Weiping Zhao, Yueping Zhang, and A. David Rodrigues. 2095


Metabolism and Excretion of 6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 Inhibitor, in Rats and Dogs and Assessment of Its Metabolic Profile in Plasma of Humans. Lin Xu, Caroline Woodward, Jing Dai, and Chandra Prakash. 2133

In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. Raman Sharma, Thomas S. McDonald, Heather Eng, Chris Limberakis, Benjamin D. Stevens, Sheena Patel, and Amit S. Kalgutkar. 2148

Assessment of the Roles of P-glycoprotein and Cytochrome P450 in Triptolide-induced Liver Toxicity in Sandwich-Cultured Rat Hepatocyte Model. Xiao-Mei Zhuang, Guo-Lin Shen, Wei-Bin Xiao, Yan Tan, Chuang Lu, and Hua Li. 2158

Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir. Evan D. Kharasch and Kristi Stubbert. 2166

RNA-Sequencing Quantification of Hepatic Ontogeny of Phase-I Enzymes in Mice. Lai Peng, Julia Y. Cui, Byunggil Yoo, Saymedha S. Gunewardena, Hong Lu, Curtis D. Klaassen, and Xiao-bo Zhong. 2175

Two Polymorphic Variants of ABCC1 Selectively Alter Drug Resistance and Inhibitor Sensitivity of the Multidrug and Organic Anion Transporter Multidrug Resistance Protein 1. Gwenaelle Conseil and Susan P.C. Cole. 2187


Lymphatic Absorption, Metabolism, and Excretion of a Therapeutic Peptide in Dogs and Rats. Yan Zou, Thomas J. Bateman, Christine Adreani, Xiaolan Shen, Paul K. Cunningham, Bo Wang, Tu Trinh, Amy Christine, Xuening Hong, Christian N. Nunes, Chris V. Johnson, Andy S. Zhang, Steve J. Staskiewicz, Matthew Braun, Sanjeev Kumar, and Vijay Bhasker G. Reddy. 2206


Supplemental material is available online at http://dmd.aspetjournals.org.